Τόμος 18 (2004) – Τεύχος 3 – Άρθρο 1 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 18 (2004) – Issue 3 – Article 1 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

Title Nasal bone as an ultrasonographic marker for down syndrome
Authors Katerina Lykeridou, Klairy Gourounti and Ploutarchos Kourtis 

Department of Midwifery, Technological Educational Institution of Athens, Athens, Greece

Citation Lykeridou, K., Gourounti, K., Kourtis, P.: Nasal bone as an ultrasonographic marker for down syndrome, Epitheorese Klin. Farmakol. Farmakokinet. 18(3): 255-260 (2004)
Publication Date Received for publication: 15 June 2004 

Accepted for publication: 1 September 2004

Full Text Language English
Order – Buy  Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)

pharmakonpress[at]pharmakonpress[.]gr

Keywords Ultrasound, fetal nasal bone, Down syndrome, screening.
Other Terms review article
Summary The objective of this review article is to inform about the role of the ultrasonographic appearance of the fetal nasal bone in the prenatal screening for the diagnosis of the Down syndrome. During the pregnancy the identification of affected fetuses is dependent on sonographic markers, such as nuchal translucency, nuchal fold, pyelectasis, hyperechoic bowel, echogenic intracardiac foci. Today the appearance of the fetal nasal bone can be used as a new promising ultrasonographic marker for the Down syndrome during the pregnancy. Normally the fetal nasal bone is sonographically apparent at 11 weeks of gestation and the fetal nasal bone length increases with the increase of the crown-rump rump length of the fetus. The absence or the hypoplasia of a nasal bone is associated with a high risk for trisomy 21 and it is a highly sensitive and specific marker for this chromosomal abnormality. Recently the nasal bone has been shown to be absent in the majority of the fetuses with Down syndrome, compared with a small percentage of normal fetuses. Therefore a short or an absent nasal bone is associated with an increased likelihood ratio for fetal Down syndrome. The addition of the fetal nasal bone in the prenatal screening for the detection of the Down syndrome can increase the detection rate and decrease the false positive rate.
References 1.    Down Langdom: Observations on an ethnic classification of idiots. Clinical Lectures and Reports, London Hospitals: 259-62 (1866)

2.    Twining P., McHugo J., Pilling D.: Textbook of Fetal Abnormalities. P. 346, Churchill Livingstone, London, 2000

3.    Sandikcioglu M., Moisted K., Kjaer I.: The prenatal development of the human nasal and vomeral bones. J. Craniol. Genet. Dev. Biol. 14: 124-134 (1994)

4.    Guis F., Ville Y., Vincent Y., Doumere S.: Ultrasound evaluation of the length of the fetal nasal bone throughout gestation. Ultrasound Obstet. Gynecol. 5: 304-307 (1995)

5.    Stempfle N., Huten Y., Fredouille C., et al.: Skeletal abnormalities in fetuses with Down syndrome: a radiographic post-mortem study. Pediatr. Radiol. 29: 682-688 (1999)

6.    Cicero S., Curcio P., Papageorgiou A., Sonek J., Nicolaides K.: Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an observational study. Lancet 355: 1665-1667 (2001)

7.    Cicero S., Sonek J., McKemma D., Croom C., Johnson L., Nicolaides K.: Nasal bone hypoplasia in trisomy 21 at 15-22 weeks gestation. Ultrasound Obstet. Gynecol. 21: 15-18 (2002)

8.    Sonek J., Nicolaides K.: Prenatal ultrasonographic diagnosis of nasal bone abnormalities in three fetuses with Down syndrome. Am. J. Obstet. Gynecol. 186: 139-141 (2002)

9.    Cicero S., Bindra Ft., Rembouskos G., Tripsanas C., Nicolaides K.H..:Fetal nasal bone length in chromosomally normal and abnormal fetuses at 11-14 weeks of gestation. J. Matern. Fetal Neonatal. Med. 11: 400-402 (2002)

10.  Monni G., Zoppi M., Ibba R.: Absence of nasal bone and detection of trisomy 21. Lancet 359:1343 (2002)

11.  Bromley B., Lieberman E., Shipp T., Benaccerraf B.: Fetal nose bone length, a marker for Down syndrome in the second trimester. J. Ultrasound Med. 21: 1387-1394 (2002)

12.  Cicero S., Bindra R., Rembouskos G., Spenser K., Nicolaides K.: Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent nasal bone, free beta-h CG and PAPP-A at 11 to 14 weeks. Prenat. Diagn. 23: 306-310 (2003)

13.  Cicero S., Longo D., Rembouskos G., Sacchini C., Nicolaides K.: Absent nasal bone at 11-14 weeks of gestation and chromosomal defects. Ultrasound Obstet. Gynecol. 22: 31-35 (2003)

14.  Orlandi F., Bilardo C., Campogrande M., Kranlz D., et al.: Measurement of nasal bone length at 11-14 weeks of pregnancy and its potential role in Down syndrome risk assessment. Ultrasound Obstet. Gynecol. 22: 36-39 (2003)

15.  Kanellopoulos V., Katsetos C., Economides D.: Examination of fetal nasal bone and repeatability of measurement in early pregnancy. Ultrasound Obstet. Gynecol. 22: 131-134 (2003)

16.  Vintzileos A., Walters C., Yeo L.: Absent nasal bone in the prenatal detection of fetuses with trisomy 21 in a high risk population. Obstet. Gynecol. 101: 905-908 (2003)

17.  Lee W., DeVore GR., Comstock CH., et al.: Nasal bone evaluation in fetuses with Down syndrome during the second and third trimester of pregnancy. J. Ultrasound Med. 22: 55-60 (2003)

18.  Cicero S., Rembouskos G., Vandecruys H.. Hogg M., Nicolaides K.: Likelihood ratio for trisomy 21 in fetuses with absent nasal bone at the 11-14 weeks scan. Ultrasound Obstet. Gynecol. 23: 218-223 (2004)

19.  Prefumo F., Sairam S., Bhide A., Penna L., et al.: Maternal ethnic origin and fetal nasal bones at 11-14 weeks of gestation. Br. J. Obstet. Gynecol 111: 109-112 (2004)

20.  Chen M., Lee C., Leung K., et al.: Pilot study on the midsecond trimester examination of fetal nasal bone in the Chinese population. Prenatal Diagn. 24: 87-91 (2004)

Relative Papers

Online ISSN 1011-6575

Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:

Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor

Τι είναι η Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση-Οδηγίες προς τους Συγγραφείς – 
What is Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition-Instrunctions to Authors

Άρθρα Δημοσιευμένα στην Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – 
Articles Published in Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

Συντακτικη Επιτροπή-Editorial Board

ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2004 – ANNUAL SUBSCRIPTION 2004
Γλώσσα Πλήρους Κειμένου – Full Text Language Αγγλικά – English
Παραγγελία – Αγορά – Order – Buy Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)

pharmakonpress[at]pharmakonpress[.]gr

Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)

pharmakonpress[at]pharmakonpress[.]gr

 

 

 

Bookmark the permalink.

Comments are closed.